Rayner’s clear vision for the future of cataract surgery

Article

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Rayner designs and manufactures IOLs and proprietary injection devices for use in cataract surgery. As the first manufacturer of the IOL, they’ve been working with surgeons for longer than anyone.

Today, Rayner are bringing new impetus to this focus with the opening of The Ridley Innovation Centre, a new £20million R&D, training and production facility in Worthing, West Sussex, United Kingdom. This IOL production facility has the capability of manufacturing 3 million intraocular lenses each year.

In addition, their new Enterprise Resource Planning (ERP) quality system enables them to trace every lens from source materials to a patient’s eye. What’s more, Rayner is the only IOL manufacturer in the UK and their investment represents commitment to delivering competitive high quality technology from a well-trained UK manufacturing team.

Their mission statement is to “exist to enable surgeons to focus on what matters: improving patient’s sight. We aim to remain at the forefront of innovation, developing clinically superior ophthalmic tools that aid and streamline the surgical process, with the ultimate objective of improving sight and quality of life.”

Furthermore, Rayner’s aim has always been to provide cataract surgeons with high-quality, innovative and simple solutions which enable superior patient outcomes.

New centre

 


The new centre was also designed with the surgeon at its heart to enable training, education and research. Featuring a wet lab, library, training facilities and even a museum on the history of the IOL, this enables Rayner to engage and partner surgeons and academics in new product development.

Testament to this culture is a product pipeline of 11 new products in 3 years planned to transform Rayner into one of the leading manufacturers of IOLs.

Tim Clover, CEO, explains the significance of the new building: “The opening of The Ridley Innovation Centre marks a significant step in what we plan to be an exciting, transformative period of growth ahead of Rayner. This major investment will treble our manufacturing capacity and put us in the best position to support the company’s ambitious business expansion.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.